Post-blepharoplasty ectropion management: therapeutic benefits of platelet-rich plasma and polydeoxyribonucleotide injections

Abstract

Background Ectropion, a common complication after lower blepharoplasty, causes significant patient discomfort and dissatisfaction, yet effective treatments remain lack ing. In this study, we evaluated the efficacy of intradermal injections of polydeoxyribo nucleotide (PDRN) and platelet-rich plasma (PRP) for scar regeneration and the rapid recovery of temporary ectropion following lower blepharoplasty. Methods This retrospective study analyzed 21 cases of ectropion among 420 patients who underwent transcutaneous lower blepharoplasty between January 2020 and Oc tober 2022. PDRN and PRP were injected intradermally into the lower eyelid, with pa tients monitored at 1- or 2-week intervals. We investigated patient satisfaction, the to tal number of injections administered, and the time to complete improvement of the ectropion. Results The average time for complete ectropion resolution was 9.3 weeks, with a rela tively high patient satisfaction rating (mean, 4.3 out of 5). Ten primary cases responded well to a single injection, whereas all six patients with previous operations required two or more injections. The rate of improvement was faster than previously reported, likely due to the enhanced collagen synthesis and anti-inflammatory effects of PDRN, along with the tissue repair and angiogenic properties of PRP. Conclusions Intradermal injections of PDRN and PRP demonstrated promising results in rapidly resolving ectropion after lower blepharoplasty, thereby reducing patient dis comfort and increasing overall satisfaction.